These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 9921803)

  • 1. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients.
    Humar A; Uknis M; Carlone-Jambor C; Gruessner RW; Dunn DL; Matas A
    Transplantation; 1999 Jan; 67(1):94-7. PubMed ID: 9921803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
    Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants.
    Sawyer MD; Mayoral JL; Gillingham KJ; Kramer MA; Dunn DL
    Arch Surg; 1993 Feb; 128(2):165-9; discussion 170. PubMed ID: 8381646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
    Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
    Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
    Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal valganciclovir prophylaxis significantly reduces episodes of first-year cytomegalovirus disease and biopsy-proven acute rejection in kidney transplant recipients.
    Tu PT; Shu KH; Cheng CH; Chen CH; Yu TM; Chuang YW; Huang ST; Tsai SF; Cheng CY; Wu MJ
    Transplant Proc; 2014; 46(2):574-7. PubMed ID: 24656016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R
    Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic rejection: the next major challenge for pancreas transplant recipients.
    Humar A; Khwaja K; Ramcharan T; Asolati M; Kandaswamy R; Gruessner RW; Sutherland DE; Gruessner AC
    Transplantation; 2003 Sep; 76(6):918-23. PubMed ID: 14508354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir.
    Dunn DL; Mayoral JL; Gillingham KJ; Loeffler CM; Brayman KL; Kramer MA; Erice A; Balfour HH; Fletcher CV; Bolman RM
    Transplantation; 1991 Jan; 51(1):98-106. PubMed ID: 1846255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
    Shah AP; Chen JM; Fridell JA
    Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.